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Abstract
Type 1 diabetes (T1D) is an autoimmune proinflammatory disease with no effective inter-
vention. A major obstacle in developing new immunotherapies for T1D is the lack of means
for monitoring immune responsiveness to experimental therapies. The LEW1.WR1 rat
develops autoimmunity following infection with the parvovirus Kilham rat virus (KRV) via
mechanisms linked with activation of proinflammatory pathways and alterations in the gut
bacterial composition. We used this animal to test the hypothesis that intervention with
agents that block innate immunity and diabetes is associated with a shift in the gut micro-
biota. We observed that infection with KRV results in the induction of proinflammatory gene
activation in both the spleen and pancreatic lymph nodes. Furthermore, administering ani-
mals the histone deacetylase inhibitor ITF-2357 and IL-1 receptor antagonist (Anakinra)
induced differential STAT-1 and the p40 unit of IL-12/IL-23 gene expression. Sequencing of
bacterial 16S rRNA genes demonstrated that both ITF-2357 and Anakinra alter microbial
diversity. ITF-2357 and Anakinra modulated the abundance of 23 and 8 bacterial taxa in
KRV-infected animals, respectively, of which 5 overlapped between the two agents. Lastly,
principal component analysis implied that ITF-2357 and Anakinra induce distinct gut micro-
biomes compared with those from untreated animals or rats provided KRV only. Together,
the data suggest that ITF-2357 and Anakinra differentially influence the innate immune sys-
tem and the intestinal microbiota and highlight the potential use of the gut microbiome as a
surrogate means of assessing anti-inflammatory immune effects in type 1 diabetes.
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Introduction
Type 1 diabetes (T1D) is a proinflammatory disorder that leads to the specific destruction of
insulin producing beta cells. It is thought that a combination of both genetic and environmen-
tal factors play a key role in disease mechanisms [1]. The majority of the T1D patients develop
beta-cell-specific autoantibodies before disease onset [1]. Moreover, in some patients, the
appearance of autoantibodies precedes hyperglycemia by many years [1]. The period of time
between seroconversion and diabetes provides an opportunity for disease prevention.
The intestinal microbiota plays an essential role in gut development, metabolism, and
immunity (reviewed in refs. [2]). Emerging data from humans and animals have suggested
that alterations in the gut microbiota are linked with a number of metabolic and immune dis-
orders, including T1D [3–5]. Furthermore, humans with genetic susceptibility to islet autoim-
munity have altered intestinal microbiomes [3, 5, 6], but the role of these alterations in disease
pathogenesis remains to be determined [7].
One of the most critical problems that clinical trials in the field of T1D currently face is the
lack of non-invasive methods for monitoring effects of experimental immunomodulatory
agents [8]. Clinical trials have used a number of metabolic outcomes such as the C peptide
response following a mixed-meal tolerance test, HbA1c levels, and insulin usage, to assess
effects induced by experimental drugs on the disease status. However, in a significant portion
of previous trials 1) clinical effects in the treatment versus the placebo groups were not
detected [9, 10], 2) an effect was observed only in a subset of treated individuals [11], or 3) the
effect was not durable despite continuous drug administration [12]. Therefore, there is a press-
ing need for new strategies, to better monitor potential responses to immunotherapies.
The LEW1.WR1 rat develops islet autoimmunity following infection with the parvovirus
Kilham Rat Virus (KRV) (reviewed in ref. [13]). The diseases closely resembles the human dis-
order in terms of histopathology, pathogenesis, lack of sex bias, and MHC class II association
[14]. Diabetes can be detected in the LEW1.WR1 rat beginning at 14 days following virus
infection [15]. We recently demonstrated that the innate immune system plays a key role in
the mechanism triggering beta cell autoimmunity in the BioBreeding Diabetes Resistant and
LEW1.WR1 rats [4, 15–17]. Indeed, activation of the innate immune system with TLR ago-
nists, such as the viral mimic polyinosinic: polycytidylic acid (poly I:C) or CpG DNA, followed
by infection with KRV substantially exacerbates diabetes [18, 19]. Moreover, infection with
KRV leads to a robust proinflammatory response linked with the up-regulation of a vast array
of proinflammatory cytokines and chemokines in the spleen, pancreatic lymph nodes and
Peyer’s patches via mechanisms that involve TLR9 pathways [4, 17, 18]. Lastly, modulation of
virus-induced innate immunity with steroids [18], IL-1 receptor antagonist [16], histone dea-
cetylase inhibitors [15], or antibiotics [4] ameliorates disease development.
Herein, we used the LEW1.WR1 rodent model to test the possibility that the intestinal
microbiome may be used as a tool of monitoring effects induced by experimental immuno-
therapies. For this purpose, we analyzed the effect of histone deacetylase inhibitor ITF-2357
(reviewed in ref. [20]) and IL-1 receptor antagonist (Anakinra, reviewed in ref. [21]) on the
innate immune system and intestinal microbiome. We have previously shown that treatment
with Anakinra and ITF-2357 interferes with islet autoimmunity and prevents beta cell destruc-
tion [15, 16]. Our data indicate that ITF-2357 and Anakinra differentially modulate virus-
induced innate immunity and the gut bacterial composition early in the disease course. The
data underscore novel opportunities for using the gut microbiome as a potential tool to detect
drug-induced immune effects in individuals undergoing experimental immunotherapies.
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Materials and methods
Animals, viruses, and innate immunity blockade
LEW1.WR1 rats were bred and housed in our specific pathogen-free facility. This study was
carried out in strict accordance with the recommendations in the Guide for Care and Use of
Laboratory Animals of the National Institutes of Health. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the University of Colorado Denver (per-
mit number: B-79715(10)1E). To test the hypothesis that therapy with Anakinra and ITF-2357
modulate the gut microbiota, rats at the age of 21–25 days were divided into 6 control and
experimental groups. Group 1 was left untreated (control uninfected). Group 2 was injected i.
p. with 1 x 107 PFU of KRV only, whereas Group 3 and Group 4 were i.p. injected with Ana-
kinra on 5 consecutive days (50 μg/g body weight, obtained from Amgen, Thousand Oaks,
CA) and were uninfected or infected with KRV, respectively (Fig 1). Group 5 and Group 6
were gavaged with ITF-2357 on 5 consecutive days (30 μg/g body weight, obtained from Ital-
farmaco, Milano, Italy) and were uninfected or KRV infected, respectively. Fecal samples were
collected on day 5 post-infection and frozen immediately at -80 degrees until use.
High-throughput DNA sequencing for microbiome analysis
Bacterial profiles were determined by broad-range analysis of 16S rRNA genes following our
previously described methods [4]. In brief, DNA was extracted from fecal specimens using the
QIAmp DNA stool mini kit (Qiagen, Valencia, CA). Broad-range PCR amplicons were
Fig 1. Treatment of LEW1.WR1 rats with Anakinra and ITF-2357. LEW1.WR1 rats at the age of 21–25 days were left untreated
or infected with KRV. They were left with no further treatment of administered Anakinra or ITF-2357 on 5 consecutive days as
described in Materials and Methods. The gut microbiome and KRV-induced innate immunity were analyzed on day 5 post-
infection.
https://doi.org/10.1371/journal.pone.0173968.g001
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generated using barcoded primers that target the V4 variable region of the 16S rRNA gene:
primers 534F (5’ GTGCCAGCMGCCGCGGTAA)and 806R (5’ GGACTACHVGGGTWTCTAAT).
PCR products were normalized using a SequalPrep™ kit (Invitrogen, Carlsbad, CA), pooled,
and quantified by Qubit Fluorometer 2.0 (Invitrogen, Carlsbad, CA). The pool was diluted to
4nM and denatured with 0.2 N NaOH at room temperature. The denatured DNA was diluted
to 15pM and spiked with 25% of the Illumina PhiX control DNA prior to loading the
sequencer. Illumina paired-end sequencing was performed on the Ilumina MiSeq platform
with version v2.3.0.8 of the MiSeq Control Software and version v2.3.32 of MiSeq Reporter,
using a 600 cycle version 3 reagent kit. Illumina Miseq paired-end reads were aligned to Nor-
wegian rat reference genome rn4 with bowtie2 and matching sequences discarded (ref. [22],
and Homo Sapiens UCSC Hg19 Human Genome Sequence from iGenome [http://support.
illumina.com/sequencing/sequencing_software/igenome.ilmn]). As previously described, the
paired-end sequences were sorted by sample via barcodes in the paired reads with a python
script. The sorted paired reads were assembled using phrap and pairs that did not assemble
were discarded. Assembled sequence ends were trimmed over a moving window of 5 nucleo-
tides until average quality met or exceeded 20. Trimmed sequences with more than 1 ambigu-
ity or shorter than 150 nt were discarded. Potential chimeras identified with Uchime
(usearch6.0.203_i86linux32) [23] using the Schloss [24] Silva reference sequences were
removed from subsequent analyses. Assembled sequences were aligned and classified with
SINA (1.3.0-r23838) [25] using the bacterial sequences in Silva 115NR99 [26] as reference con-
figured to yield the Silva taxonomy. Operational taxonomic units (OTUs) were produced by
clustering sequences with identical taxonomic assignments. Demultiplexed paired end
sequence data were deposited in the NCBI Sequence Read Archive under project accession
number SRP078351.
Quantitative RT-PCR
RNA extraction, cDNA synthesis, and quantitative RT-PCR were performed as previously
described [17]. The standards used for the gene amplification were TOPO plasmid vectors
(Invitrogen) expressing a *500-bp DNA fragment derived from the mRNA sequence of the
gene of interest that includes the *100-bp sequence used for the PCR amplification. The
primers were synthesized by Integrated DNA Technologies (Coralville, IA). Their sequences
have been previously published [17]. Data for gene expression in the spleen and pancreatic
lymph nodes were calculated as the ratio of gene expression to β-actin expression in the same
sample of cDNA.
Statistical analysis
The Explicet software package was used for display and diversity analysis [27]. All other data
analysis was performed using SAS (SAS Institute Inc., Cary, NC, USA) or R (www.cran.org)
software. The relative abundance (RA) of each taxon was calculated as the number of high-
quality sequences of a given taxon divided by the total number of high-quality 16S rRNA
sequences in a sample. For principal component analysis (PCA) a small constant (1/total num-
ber of sequences) was added to the sequence counts and the centered log ratio transformation
(CLR) was calculated. Shannon diversity, Shannon evenness, and richness (Sobs) were calcu-
lated using rarefaction and compared across groups using a Wilcoxon rank based test. To
compare RA of taxa across groups, a two-stage testing process was implemented. In the first
stage, an overall Wilcoxon rank based test was used to determine whether one or more groups
differed significantly from the others, and therefore select taxa of interest for further compari-
sons. If this overall p-value was significant (p<0.05), the taxa under evaluation was included in
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the second stage of testing. In this stage, pairwise differences between all groups were calcu-
lated. A false discovery rate (FDR) adjustment for multiple comparisons was applied to this
second stage of testing; comparisons with p<0.10 after FDR were considered significant. Dif-
ferences in microbiome composition (i.e., beta-diversity) between subsets were quantified by
the Bray-Curtis index using the vegan R package, which performs a non-parametric multivari-
ate analysis of variance (PERMANOVA with 10,000 replicate resamplings). Statistical compar-
isons for the qPCR data were made using ANOVA with a Bonferroni multiple-comparison
test.
Results
Anakinra and ITF-2357 modulate KRV-induced innate immunity in the
spleen and pancreatic lymph nodes
We sought to investigate whether the gut microbiome could be used as a sensor of drug-
induced immune modulation. To this end, we first analyzed the effect of Anakinra and ITF-
2357 on virus-induced innate immunity. Animals were infected with KRV and administered
Anakinra and ITF-2357 as shown in Materials and Methods and in Fig 1 (n = 6 per group).
Spleens sand pancreatic lymph nodes were removed on day 5 post-infection at the time when
inflammation is detectable in the spleen and pancreatic lymph nodes [18], and the expression
level of transcripts for STAT-1, the p40 subunit of IL-12 and IL-23 and IFN-γ was assessed by
quantitative RT-PCR. The data presented in Fig 2 indicate that infection with KRV leads to an
increase in the expression level of STAT-1 and the p40 subunit of IL-12 and IL-23 but not
IFN-γ in the spleen (p< 0.001 for both). In contrast, KRV upregulated the expression of all of
these genes in pancreatic lymph nodes (p< 0.001 for all vs. uninfected). We further found that
therapy with Anakinra but not ITF-2357 reduced STAT-1 and the p40 subunit transcript levels
in the spleen (p<0.001 for both compared with KRV only). However, both Anakinra and ITF-
2357 induced the expression of STAT-1 transcript levels in pancreatic lymph nodes (p<0.01
Fig 2. The effect of Anakinra and ITF-2357 on KRV-induced innate immunity in the spleen and pancreatic lymph nodes.
LEW1.WR1 rats were left untreated, were injected with KRV, were treated with KRV plus Anakinra or ITF-2357 (ITF) beginning
on the day of infection, or treated with Anakinra or ITF-2357 only as indicated in the figure. RNA was extracted from the spleen
(A) and pancreatic lymph nodes (B) 5 days post-infection, and the relative expression level of the indicated genes was evaluated
using quantitative RT-PCR. The results are presented as the mRNA expression of the gene of interest relative to the expression
of β-actin in tissue from individual animals. Statistical analyses were performed using an ANOVA with Bonferroni’s correction for
multiple comparisons. *p < 0.001; **p < 0.01
https://doi.org/10.1371/journal.pone.0173968.g002
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and p<0.001, respectively, versus KRV only) and moderately increased the level of the p40
subunit and IFN-γ transcripts in pancreatic lymph nodes (p>0.05). These findings suggest
that Anakinra and ITF-2357 differentially modulate proinflammatory gene expression in the
spleen.
ITF-2357- and Anakinra treatment modulates the fecal microbiome
We tested the hypothesis that treating LEW1.WR1 rats with the anti-inflammatory agents
ITF-2357 and Anakinra would alter the composition of the intestinal microbiome. Intestinal
microbiota were analyzed by bacterial 16S rRNA gene sequencing of fecal DNA on day 5 post-
infection (Fig 1). A total of 130 genus-level taxa were identified within the six control and
experimental rat groups (n = 6–7 rats per group). The highthroughput sequencing generated
1,805,321 high-quality 16S rRNA sequences (mean sequence length: 297 nt; median
sequences/sample: 48,804 [range: 23,360 to 67,825]; median Goods coverage: 99.9% at the
rarefaction point of 15,841). Fig 3 indicates that the intestinal microbiota of LEW1.WR1 rats
were dominated by the Bacteroidetes genera S24-7, Bacteroides, and Alistipes, along with the
Firmicutes bacterial families Lachnospiraceae and Ruminococcaceae. Furthermore, the abun-
dance of a number of bacterial genera such as Bacteroides, RC9-gut group, and Anaeroplasma
appeared to be different among experimental groups. These data imply that administering
LEW1.WR1 rats agents that block innate immune pathways can lead to alterations in the intes-
tinal microbiome.
ITF-2357- and Anakinra alter bacterial biodiversity
We next sought to assess the effect of the anti-inflammatory therapy on the gut bacterial diver-
sity (n = 6–7 per group). Administering ITF-2357 or Anakinra to LEW1.WR1 rats significantly
altered the fecal microbiota of both KRV-infected and uninfected animals. Differences in both
Shannon alpha diversity (p = 0.0569; Fig 4A) and Shannon evenness (p = 0.0097; Fig 4B) were
observed across the six treatment groups; in contrast, richness (Sobs) was not affected by KRV
or drug treatments. Furthermore, PERMANOVA tests indicated an overall significant differ-
ences (p<0.0001) in microbiota across the treatment groups. In this analysis, infection with
KRV was not significantly associated with alterations in the fecal microbiome composition,
(p = 0.18), whereas drug treatment (p = 0.003) and the KRVdrug interaction (p = 0.03) were
significantly linked with the gut bacterial composition (Fig 4C). These data imply that treat-
ments with HDACi and Anakinra substantially influence taxa number and abundance as well
as species evenness.
Principal component analysis reveals three distinct clusters of animals
We used principal component analysis (PCA) to further corroborate and identify differences
in the distributions of bacterial genera from treated and untreated animals (n = 6–7 per
group). Using this approach, we detected clear separation of treatment groups along principal
component axes PC1 and PC2 (Fig 5 and S1 Table). Animals that were not treated with ITF-
2357 or Anakinra clustered away from treated animals, regardless of KRV infection. The ani-
mal group administered with KRV plus ITF-2357 clustered at a distinct location, whereas the
remainder of the ITF-2357- or Anakinra-treated animals clustered together. Thus, similar to
the PERMANOVA test, KRV infection was not associated with dramatic changes in the fecal
microbiota compared with treatment with ITF-2357 or Anakinra. Biplot analysis indicated
that separation along PC1 was driven by differences in the abundances of Lactococcus and Leu-
conostoc (enriched in animals administered or ITF-2357 or Anakinra) along with Paraprevo-
tella and Arthromitus (enriched in animals administered ITF-2357 or Anakinra). Other
The microbiome as a potential surrogate marker of immune responsiveness to experimental therapies
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Fig 3. The gut microbiome in rats treated with Anakinra and ITF-2357. Stacked bar chart of median percent counts of Operational
Taxonomic Units (OTU) representing bacterial genera with a frequency of1% of total counts in the stool from subjects with and without
islet autoimmunity as indicated in the figure. The relative abundances are inferred from 16S rRNA sequence counts in datasets. The X and Y
axes represent the sample name and percentages of bacterial taxa, respectively.
https://doi.org/10.1371/journal.pone.0173968.g003
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organisms listed in Fig 5 were more influential in determining separation along PC2. Together,
the data provide further evidence that Anakinra and ITF-2357 induce substantial shifts in the
intestinal microbiome.
Specific intestinal bacterial taxa are affected by therapy with Anakinra
and ITF-2357
To identify individual taxa affected by either Anakinra or ITF-2357 therapy, relative abun-
dances were compared across groups (n = 6–7 per group) using a Wilcoxon rank based test. A
subsequent pairwise testing was conducted if a significant difference was found (p<0.05). In
the overall tests, significant differences were observed in the relative abundances of 44 of the
130 total taxa (Table 1, S2 Table). Infection with KRV resulted in alterations in the abundances
of 4 Firmicutes and 3 Proteobacteria taxa compared with naïve rats. ITF-2357 and Anakinra
also modulated the abundances of 23 and 8 intestinal taxa in infected rats, respectively, while 5
of these taxa were altered by both drugs. Among the most notable alterations induced by Ana-
kinra and ITF-2357 were 27-fold and 52-fold increases in the median abundance of the bacte-
rial genus Akkermansia, respectively (adjusted p = 0.07 and p<0.005 vs. KRV only,
respectively). ITF-2357 modulated the abundances of bacterial groups from the phyla
Fig 4. Bacterial biodiversity in animals treated with anti-inflammatory agents. Shannon alpha diversity
(A) and Shannon evenness biodiversity indices (B), respectively, across the experimental groups. The area
inside the box represents the interquartile range (IQR: 25th to 75th percentiles), the median and mean are
denoted by a line and a circle, respectively. The whiskers extend 1.5 IQR from the box, the observations
outside of this range are displayed as points. Panel C: Results of permutation-based analysis of variance
(PERMANOVA) tests across all treatment groups (under the “PERMANOVA P-Values” heading) and pairs of
treatment groups (table).
https://doi.org/10.1371/journal.pone.0173968.g004
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Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria, with the most substantial
alterations observed in the levels of Turicibacter and Candidatus-Arthromitus (i.e., segmented
filamentous bacteria). Similar to our previously published PCR findings [26, 27], the high-
throughput data from the current study indicate that KRV increases the abundances of Bifido-
bacterium and Clostridium compared with the uninfected control animals, and therapies with
ITF-2357 and Anakinra reduce the level of these genera compared with rats administered
KRV only (data not shown); however the differences seen using the present highthroughput
approach were not statistically significant probably due to the considerable differences in the
size of the data sets associated with these surveys as well as the different statistical approaches
used for data analysis.
Finally, ITF-2357 and Anakinra modulated the abundances of more than 20 taxa in the
intestine of uninfected animals, of which 11 overlapped between the two agents. Collectively,
the data suggest that therapies with either Anakinra or ITF-2357 differentially modulate the
abundances of individual bacterial taxa.
Fig 5. Principal component analysis of the intestinal microbiota from rats treated with innate immune blockers. The PCA scores
are displayed for each sample. The different colors and shapes correspond to the various treatment groups as indicated in the figure and
described in Materials and Methods. Vectors corresponding to the indicated top 10 genera with the highest loadings are displayed. The
magnitude and direction correspond to the weights.
https://doi.org/10.1371/journal.pone.0173968.g005
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Table 1. Median percent abundances of bacterial taxa in the gut from Anakinra- and ITF-2357-treated animals.
Taxa Treatment
Uninfected 6¼ KRV Anakinra KRV plus
Anakinra
ITF KRV plus
ITF
Bacteroidetes/S24-7* 31.06 33.13 29.30¶ 33.28 32.25 13.94
Bacteroidetes/Butyricimonas 0.21 0.97 0.24 0.65 0.29 1.20
Bacteroidetes/Parabacteroides 1.15 1.47 0.17 0.26 0.26 2.48
Bacteroidetes/Paraprevotella 0.00 0.00 0.06 0.02 0.04 0.05
Bacteroidetes/Prevotellaceae* 1.14 1.86 4.58 5.14 5.61 2.96
Bacteroidetes/Rikenella 0.20 0.63 0.13 0.20 0.03 0.00
Bacteroidetes/Odoribacter 0.37 0.00 0.40 0.57 0.17 0.00
Bacteroidetes/Bacteroides 7.61 10.1 6.0 2.7 4.0 14.71
Verrucomicrobia/Akkermansia 3.70 0.09 0.30 2.52 1.12 4.82
Firmicutes/Marvinbryantia 0.01 0.05 0.03 0.00 0.04 0.00
Firmicutes/Clostridiales* 0.89 0.86 1.66 2.56 1.02 0.12
Firmicutes/Clostridium 0.29 0.45 0.23 0.26 0.23 0.00
Firmicutes/Erysipelotrichaceae* 0.06 0.07 0.03 0.02 0.04 0.01
Firmicutes/Candidatus-Arthromitus 0.00 0.00 0.13 0.06 0.14 1.04
Firmicutes/Leuconostoc 0.01 0.00 0.00 0.00 0.00 0.00
Firmicutes/Turicibacter 0.70 1.12 1.92 1.89 0.63 0.02
Firmicutes/Firmicutes 0.00 0.00 0.02 0.01 0.01 0.01
Firmicutes/Weissella 0.00 0.00 0.00 0.00 0.00 0.00
Firmicutes/Roseburia 0.06 0.31 0.16 0.12 0.19 0.15
Firmicutes/Lactococcus 0.01 0.01 0.00 0.00 0.00 0.00
Firmicutes/Streptococcus 0.06 0.02 0.01 0.00 0.02 0.01
Firmicutes/Blautia 0.00 0.03 0.02 0.00 0.02 0.01
Firmicutes/Pseudobutyrivibrio 0.01 0.00 0.00 0.00 0.00 0.00
Firmicutes/Ruminococcaceae* 8.39 7.11 16.23 9.91 14.38 9.76
Firmicutes/Ruminococcus 0.68 1.05 0.96 0.89 0.19 0.05
Firmicutes/RC9-gut-group 4.34 4.42 1.90 2.53 1.30 0.49
Firmicutes/Haemophilus 0.02 0.01 0.01 0.00 0.01 0.04
Firmicutes/Peptococcaceae* 0.21 0.23 0.53 0.24 0.40 1.05
Firmicutes/RF9 0.02 0.62 0.31 0.25 0.08 0.01
Firmicutes/Coprococcus 0.03 0.11 0.06 0.08 0.05 0.72
Firmicutes/Carnobacteriaceae* 0.00 0.00 0.00 0.00 0.00 0.00
Firmicutes/Anaerovorax 0.00 0.01 0.02 0.03 0.01 0.01
Firmicutes/Peptostreptococcaceae* 1.63 1.48 2.43 1.87 1.43 0.52
Proteobacteria/γ-proteobacteria* 0.00 0.00 0.00 0.00 0.00 0.00
Proteobacteria/Escherichia-Shigella 0.01 0.03 0.00 0.01 0.04 0.19
Proteobacteria/Thalassospira 0.01 0.39 0.21 0.43 0.12 0.46
Proteobacteria/Acinetobacter 0.00 0.00 0.00 0.00 0.00 0.00
Proteobacteria/Enterobacteriaceae* 0.00 0.00 0.00 0.00 0.00 0.00
Proteobacteria/Helicobacter 0.03 0.00 0.00 0.06 0.00 0.00
Proteobacteria/Bilophila 0.00 0.00 0.00 0.00 0.02 0.00
Actinobacteria/Collinsella 0.00 0.00 0.00 0.00 0.00 0.00
Actinobacteria/Bifidobacterium 0.15 0.51 0.16 0.14 0.12 0.02
Candidate-division-TM7* 0.01 0.00 0.02 0.02 0.03 0.00
¶The highlights in the KRV column represent significant differences compared with uninfected rats; the highlights in the Anakinra and ITF-2357 columns
represent significant differences versus the uninfected control; the highlights in the KRV plus Anakinra or KRV plus ITF-2357 represent significant
differences compared with KRV.
6¼The levels of significance for these comparisons are indicated in S2 Table.
*Entry represents a higher-order group of taxa that could not be assigned to finer levels of taxonomic resolution. All other taxa represent genus-level
classifications.
https://doi.org/10.1371/journal.pone.0173968.t001
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Discussion
Numerous clinical trials have been conducted in the last twenty years to treat T1D, however
the disease remains without known etiology or effective immunotherapeutic interventions
[28]. One of the major reasons for this failure is the lack of suitable means to monitor effects of
experimental immunotherapies on the immune system. Indeed, there is a consensus that new
non-invasive clinical means are urgently needed to promote the discovery of new interven-
tions for T1D [28]. Importantly, data indicating whether a potential immunotherapy can mod-
ulate immunity are crucial even if the trial itself fails to show clinical efficacy [28]. Herein, we
used the LEW1.WR1 rat model of virus-induced inflammation and diabetes to test the effect
of anti-inflammatory therapies with Anakinra and ITF-2357 on innate immunity and the
intestinal microbiome shortly after commencing the therapy. We present data indicating that
in addition to altering the innate immune system, intervention with Anakinra and ITF-2357
differentially modulates the gut bacterial structure as reflected by shifts in the overall gut bacte-
rial microbiomes and bacterial diversity and alterations in the abundance of individual bacte-
rial taxa, most notably those of the Bacteroidetes phylum. Based on these findings, we propose
that alterations in the intestinal microbiota could potentially be used as a surrogate tool to
detect immune responsiveness to experimental immunotherapies.
How therapy with Anakinra or ITF-2357 modulates the level of commensal bacteria is
unclear. In addition, it remains to be identified whether the affected gut microbes are directly
linked with mechanisms of autoimmunity. Owing to the interdependence between the
immune system and the gut microbiota [29, 30], we postulate that the differential effect exerted
by Anakinra and ITF-2357 on the gut microbiome might be associated at least in part with dif-
ferent effects they have on the immune system. Indeed, data from the present and our earlier
studies [15, 16] are in accordance with the possibility that Anakinra and ITF-2357 induce a dif-
ferential effect on the KRV-induced innate immunity. This difference could be linked with the
fact that Anakinra inhibits the IL-1 signaling pathway by binding to the IL-1R1 [31], whereas
ITF-2357 suppresses class I and class II histone deacetylases and may therefore induce broader
effects on immunity [32]. In any case, both Anakinra and ITF-2357 were observed to alter
cytokine expression in various experimental systems [33, 34]. Additional studies are necessary
to establish whether a cause-and-effect relationship exists between ITF-2357- and Anakinra-
induced alterations in innate immunity and the gut bacterial composition.
One of the most dramatic alterations induced by therapies with ITF-2357 and Anakinra was
a 30-50-fold increase in the median abundance of the Verrucomicrobia genus Akkermansia
that was modulated by both drugs. It may be hypothesized that this increase is associated with
potential anti-inflammatory effects induced by ITF-2357 and Anakinra. Indeed, the level of the
Akkermansia species A. muciniphila, a mucin-degrading bacteria residing in the mucus layer
was reported to induce a beneficial effect on diabetes in NOD mice [35]. Another interesting
result was the ITF-2357-induced increase in the abundance of the Firmicutes taxon Candida-
tus-Arthromitus. Candidatus-Arthromitus is the segmented filamentous bacteria (SFB) that has
been associated with both diabetes induction and prevention (reviewed in ref. [36]). Finally, we
observed that therapy with ITF-2357 led to an increase in the abundance of a number of Bacter-
oidetes taxa including the Bacteroides genus. This shift could promote an anti-inflammatory
environment, since Bacteroides can induce Treg cells and anti-inflammatory cytokine expres-
sion and inhibit NF-κB signaling pathways [37] although some members of the Bacteroides
genus were also shown to promote pro-inflammatory pathways in humans and mice [38].
Whether alterations in the abundances of the above taxa could be useful in assessing drug-
induced immune modulation in subjects undergoing anti-inflammatory therapies remains to
be determined in future clinical trials. In any case, this possibility is consistent with data from
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other disorders. For example, a previous report demonstrated a correlation between a shift in
the gut microbiota and the response to steroid treatments in individuals with ulcerative colitis
[39]. Another study provided evidence for alterations in the gut microbiome from subjects
using metformin and statins [40]. Indeed, subjects who used metformin had an increased abun-
dance of Escherichia coli and a positively correlated with pathways associated with the degrada-
tion and utilization of D-glucarate and D-galactarate and pyruvate fermentation [40].
Why Anakinra and ITF-2357 induce a differential effect on the spleen versus pancreatic
lymph nodes is unclear but could be linked with differences in the composition and function
that exist between these lymphoid organs [41]. It remains to be determined whether and how
innate pathways affected by Anakinra- and ITF-2357 are directly linked to mechanisms of islet
autoimmunity. Likewise, whether Anakinra- and ITF-2357-induced alterations in the abun-
dance of gut bacteria can be used as a biomarker of therapy outcome awaits further
investigation.
In conclusion, we show that two different anti-inflammatory drugs that modulate innate
immunity and the gut microbiome and innate immunity in diabetes-susceptible animals.
These observations have important clinical implication as they point to the possibility that the
gut microbiome could potentially be harnessed as a novel means to facilitate drug discovery in
T1D and potentially other autoimmune disorders.
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